Health
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
COPENHAGEN, Denmark, April 13, 2026--Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in combination with bevacizumab in patients with advanced ovarian cancer, showed a safety profile consistent with the known safety profiles of Rina-S and bevacizumab. These data are from the combination therapy cohort D2 of the m
About this update from Genmab A/s
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/33736940ecb322b73dbbaa4f9ac295ae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/42m.r5KsG9ycqOVtLOoR7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4MA--/https://media.zenfs.com/en/business-wire.com/33736940ecb322b73dbbaa4f9ac295ae","width":960,"height":280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/rpGtIHIp5LB2JahSkuY_tA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MDA-/https://media.zenfs.com/en/business-wire.com/33736940ecb322b73dbbaa4f9ac295ae","width":1200,"height":350}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer","length":182,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The ongoing Phase 3 RAINFOL-04 trial will further evaluate the combination in patients with recurrent platinum-sensitive ovarian cancer (PSOC)","length":142,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":324,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, April 13, 2026--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in combination with bevacizumab in patients with advanced ovarian cancer, showed a safety profile consistent with the known safety profiles of Rina-S and bevacizumab. These data are from the combination therapy cohort D2 of the multi-part Phase 1/2 RAINFOL™-01 study and were presented during an oral session at the 2026 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO) in San Juan, Puerto Rico.","length":705,"tagName":"p"},{"type":"text","content":""Advanced ovarian cancer is a complex and difficult-to-treat disease, and the ability for investigational therapies such as Rina-S to be safely combined with bevacizumab can provide clinicians with more options to help improve disease control and manage resistance," said Cara Mathews, M.D., study invest...